1. Cramer advised selling BP after mixed earnings results. 2. Cencora's acquisition of OneOncology totals $5 billion. 3. Perpetua missed earnings estimates, affecting its stock negatively. 4. BP's revenue fell short of analyst expectations despite profit. 5. Cencora's shares rose 1.3%, indicating market confidence.